Your NEJM Group Today: Incisional Keloid, Being Taught to Teach, Washington IM Opportunity (FREE)
By The Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: …
Publication date: Available online 16 October 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): A. Regan, J. McMahon
No abstract available
Keloid disorder, a recently coined term, refers to a group of fibroproliferative disorders affecting the skin (Tirgan, 2019a). The clinical spectrum of such conditions include keloids and hypertrophic scars, as well as acne keloidalis and keloidalis nuchae, in which cutaneous nodules and tumors develop as a result of trauma and inflammation (Figure 1). Keloids are relatively common, particularly affecting certain ethnic groups. Individuals of African ancestry have a very high incidence of keloids, reported to affect 4-16% of people in such populations, i.e., about 15 times higher than in individuals of European ancestry (Brown et al.
We wish to discuss the complications of free flap reconstructive surgery of the head and neck in a patient with mild protein S deficiency.
This study revealed that circRNAs are potentially implicated in the development of keloid and could serve as novel diagnostic and therapeutic targets. PMID: 31612410 [PubMed - as supplied by publisher]
This article discusses techniques for prevention and treatment options for unsightly and hypertrophic scars. PMID: 31587770 [PubMed - in process]
This article discusses techniques for prevention and treatment options for unsightly and hypertrophic scars.
ConclusionThis is the first report to suggest that female sex may drive keloidogenesis because of physiological reasons. Individuals were most likely to seek a medical examination almost 10 years after onset, regardless of sex. These findings provide new insight into the importance of sex in the development and progression of keloids. Future studies should address the influence of sex hormones on the keloid.
French medical company BILHI Genetics has become the first to develop a first-of-its-kind test that, it says, is able to identify genes linked to a risk of keloid scars.
Conclusions: Early postoperative botulinum toxin type A injection in the medial canthal region efficiently reduces hypertrophic scarring and improves the outcome of epicanthoplasty. Therefore, botulinum toxin type A injection can be used as a routine method to prevent hypertrophic scarring and improve the outcome of epicanthoplasty. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.